相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity?
Kati Choi et al.
INFLAMMATORY BOWEL DISEASES (2019)
Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury
Hamzah Abu-Sbeih et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma
Hamzah Abu-Sbeih et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis
Yinghong Wang et al.
INFLAMMATORY BOWEL DISEASES (2018)
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
Kristian M. Hargadon et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity
John A. Thompson
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-Small Cell Lung Cancer
Jang Ho Cho et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson
Yinghong Wang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis
Hamzah Abu-Sbeih et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
Yinghong Wang et al.
NATURE MEDICINE (2018)
Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study
Hamzah Abu-Sbeih et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report
Jumpei Kashima et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer
Hisato Kawakami et al.
INVESTIGATIONAL NEW DRUGS (2017)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2017)
Management of acute cholecystitis in cancer patients: a comparative effectiveness approach
Thejus T. Jayakrishnan et al.
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES (2014)
The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM
Stephen B. Edge et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Acute cholecystitis in a patient with metastatic renal cell carcinoma treated with everolimus
Bulent Cetin et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2010)
Acalculous Cholecystitis in a Patient with Metastatic Renal Cell Carcinoma Treated with Sunitinib
Gonzalo Gomez-Abuin et al.
CLINICAL GENITOURINARY CANCER (2009)
Risk of Cholecystitis in Patients With Cancer A Population-based Cohort Study in Denmark
Reimar W. Thomsen et al.
CANCER (2008)
Cholecystitis in neutropenic patients:: Retrospective study and systematic review
M Gorschlüter et al.
LEUKEMIA RESEARCH (2006)
分享论文
